within Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A16A_OtherAlimentaryTractAndMetabolismProducts.A16AB07_AlglucosidaseAlfa;

model AlglucosidaseAlfa
  extends Pharmacolibrary.Drugs.ATC.A.A16AB07;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>A16AB07</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Alglucosidase alfa is a recombinant human acid alpha-glucosidase enzyme replacement therapy approved for the treatment of Pompe disease (glycogen storage disease type II), a rare genetic disorder caused by deficiency of the lysosomal enzyme acid alpha-glucosidase. It is administered to help reduce glycogen accumulation in tissues, primarily skeletal and cardiac muscle.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics in patients with Pompe disease, both infantile-onset and late-onset, after intravenous infusion. Estimates from published clinical studies in both pediatric and adult populations.</p><h4>References</h4><ol><li><p>Nicolas, X, et al., &amp; An Haack, K (2023). Pharmacokinetics of Alglucosidase Alfa Manufactured at the 4000-L Scale in Participants with Pompe Disease: A Phase 3/4 Open-Label Study. <i>Clinical pharmacology in drug development</i> 12(12) 1185–1193. DOI:<a href=\"https://doi.org/10.1002/cpdd.1314\">10.1002/cpdd.1314</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/37705424/\">https://pubmed.ncbi.nlm.nih.gov/37705424</a></p></li><li><p>Byrne, BJ, et al., &amp; Mozaffar, T (2024). Long-term safety and efficacy of cipaglucosidase alfa plus miglustat in individuals living with Pompe disease: an open-label phase I/II study (ATB200-02). <i>Journal of neurology</i> 271(4) 1787–1801. DOI:<a href=\"https://doi.org/10.1007/s00415-023-12096-0\">10.1007/s00415-023-12096-0</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/38057636/\">https://pubmed.ncbi.nlm.nih.gov/38057636</a></p></li><li><p>Byrne, BJ, et al., &amp; Mozaffar, T (2024). Cipaglucosidase alfa plus miglustat: linking mechanism of action to clinical outcomes in late-onset Pompe disease. <i>Frontiers in neurology</i> 15 1451512–None. DOI:<a href=\"https://doi.org/10.3389/fneur.2024.1451512\">10.3389/fneur.2024.1451512</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/39494167/\">https://pubmed.ncbi.nlm.nih.gov/39494167</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end AlglucosidaseAlfa;
